PTC Therapeutics (PTCT) Posts Q4 Loss of 84c/Share

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.84), $0.02 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $7.99 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Wealthfront launches custodial account with tax-gain harvesting
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance